Barlow Crosby (birchlute2)

(p=0.004). Postoperative complications were observed in 14 (23.3%) patients. These were more frequent in female patients (p=0.001), with sloughed, gangrenous perforated appendix (p=0.034) and complex mass (p=0.008). Superficial wound infection was the most common complication noted in 9 (15%) patients. In 5 (8.3%) children, deep seated intra-abdominal collections were found. The mean hospital stay was 3.4 + 1.5 days. Conclusion Early surgery in pediatric patients with appendicular mass was found feasible with minimal complications. This obviated the need of prolonged follow-up and interval appendectomy with its inherent risks. Key Words Appendicular mass, Appendicular lump, Appendectomy, Child. To assess the impact of emollient therapy on gain in weight and length among preterm and low birth weight babies. Randomised controlled trial. Department of Pediatric Medicine, KEMU / Mayo Hospital Lahore, from January till June 2018. Infants with birth weight between 1.5 and 2.5 Kgs or preterm neonates born between 28 and 37 completed weeks of gestation were included in the study. Neonates with genetic syndrome, infection or with a history of admission in NICU due to any reason, were excluded.They were randomly divided into two groups-A and B, by lottery method. Mothers of the neonates in group A were advised massage with sunflower oil; while mothers of the neonates in group B were advised massage without any emollient. Babies were closely followed up and their weight and length were measured at two months of age and were analysed using SPSS version 23.0. For 140 neonates, the mean increase in weight was 489.84 ± 297.48 grams among group-A neonates (emollient therapy group) and it was 373.43 ± 276.ght neonates. Emollient therapy is an effective non-pharmacological intervention for increasing weight and length in low birth weight and preterm neonates. Key Words Emollient, Massage, Low birth weight, Preterm neonates, Weight, Length. To determine the effect and safety of sequential treatment with the low-molecular-weight heparin dalteparin and the direct oral anticoagulants rivaroxaban in patients with cancer- associated venous thromboembolism (VTE). Observational study. Department of Oncology, the Second Affiliated Hospital of Soochow University, between January 2017 and September 2019. Patients with active cancer, diagnosed with VTE and who received sequential treatment with dalteparin and rivaroxaban, were retrospectively reviewed. Logistic regression analysis was used to identify risk factors associated with VTE recurrence. Ninety-nine patients with active cancer were enrolled in the study. The median delteparin treatment time was nine days (5-20 days), and 2.8 months (1-6 months) for rivaroxaban. Sixty (60.6%) patients had eliminated VTE, and 39 (39.4%) had persistent VTE, but with relieved symptoms. No major bleeding was observed. Aloxistatin Eleven (11.1%) patients had minor bleeding, including melena (5.1%), hematuria (3.0%), vaginaclinical practice, the treatment duration is often insufficient, so it is essential to follow-up these patients to ensure sufficient treatment time. Key Words Venous thromboembolism, Low-molecular-weight heparins, Directly oral anticoagulants, Cancer. To investigate the prognostic value of tumor diameter in the short term of 3 and 5 years in patients operated for gastric cancer. A descriptive study. Kartal Dr Lütfi Kırdar City Hospital, Istanbul, Turkey, from January 2014 to December 2018 Methodology A total of 125 patients with stage 2 or 3 gastric cancer, followed up in the Department of General Surgery, were included. Demographic information, clinical, laboratory, and pathology reports were analysed in terms of postoperative 30-day mortality. The mean age of the patients was 63.9±11.9 (31-88) years. Forty-four (35.2%) were in stage 2, and 81 (64.8%)